Edinah Mudimu

Dr. Edinah Mudimu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2025 in Journal of the International AIDS Society
Verified
Journal Article
Open access
BNBrooke Nichols
Brooke Nichols
EGElvin H. Geng
Elvin H. Geng
EMEric Moakley
Eric Moakley
APAndrew N. Phillips
Andrew N. Phillips
JIJeffrey W. Imai‐Eaton
Jeffrey W. Imai‐Eaton
AGAnna Grimsrud
Anna Grimsrud

31 December 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EMEdinah Mudimu
Edinah Mudimu
KPKathryn Peebles
Kathryn Peebles
ZMZindoga Mukandavire
Zindoga Mukandavire
ENEmily Nightingale
Emily Nightingale
MSMonisha Sharma
Monisha Sharma
ABAnna Bershteyn
Anna Bershteyn
Background: Pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV and has the potential to significantly impact the HIV epidemic. Given limited resources for HIV prevention, identifying PrEP provision strategies that maximize impact is critical. Methods: We used a stochastic individual-based network model to evaluate the direct (infections prevented among PrEP users) and indirect (infections prevented among non-PrEP users as a result of PrEP) benefits of PrEP, the person-years of PrEP required to prevent one HIV infection, and the community-level impact of providing PrEP to populations defined by gender and age in western Kenya and South Africa. We examined sensitivity of results to scale-up of antiretroviral therapy (ART) and voluntary medical male circumcision (VMMC) by comparing two scenarios: maintaining current coverage (“status quo”) and rapid scale-up to meet programmatic targets (“fast-track”). Results: The community-level impact of PrEP was greatest among women aged 15–24 due to high incidence, while PrEP use among men aged 15–24 yielded the highest proportion of indirect infections prevented in the community. These indirect infections prevented continue to increase over time (western Kenya: 0.4–5.5 (status quo); 0.4–4.9 (fast-track); South Africa: 0.5–1.8 (status quo); 0.5–3.0 (fast-track)) relative to direct infections prevented among PrEP users. The number of person-years of PrEP needed to prevent one HIV infection was lower (59 western Kenya and 69 in South Africa in the status quo scenario; 201 western Kenya and 87 in South Africa in the fast-track scenario) when PrEP was provided only to women compared with only to men over time horizons of up to 5 years, as the indirect benefits of providing PrEP to men accrue in later years. Conclusions: Providing PrEP to women aged 15–24 prevents the greatest number of HIV infections per person-year of PrEP, but PrEP provision for young men also provides indirect benefits to women and to the community overall. This finding supports existing policies that prioritize PrEP use for young women, while also illuminating the community-level benefits of PrEP availability for men when resources permit.

7 February 2022 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
EMEdinah Mudimu
Edinah Mudimu
JSJack Sardinia
Jack Sardinia
SMSahar Momin
Sahar Momin
AMAndrew Medina‐Marino
Andrew Medina‐Marino
CBCharl Bezuidenhout
Charl Bezuidenhout
KPKathryn Peebles
Kathryn Peebles
Introduction: Adolescent girls and young women (AGYW) are a priority population for pre‐exposure prophylaxis (PrEP), a highly effective HIV prevention method. However, effective PrEP use among AGYW has been low. Interventions to support PrEP effective use may improve pill‐taking. Affordability of PrEP programs depends on their cost. We, therefore, evaluated the cost of community‐based PrEP with effective use counselling.Methods: Cost data from a randomized controlled trial were used to evaluate the cost of PrEP provision with effective use counselling offered to AGYW through community‐based HIV testing platforms between November 2018 and November 2019. AGYW were randomized to receive (1) group‐based community health club effective use counselling, (2) individualized effective use counselling or (3) community‐based PrEP dispensary. Task shifting of effective use counselling from nurses to trained lay counsellors was implemented in groups 1 and 2. Personnel costs were estimated from time‐and‐motion observations and staff interviews. Expenditure and ingredients‐based approaches were used to estimate costs for medical and non‐medical supplies.Results: In total, 603 AGYW initiated PrEP and accrued a total of 1280 months on PrEP. Average cost per person‐month on PrEP with group‐based community health club, individualized effective use counselling and community‐based PrEP dispensary under the Department of Health scenario were similar and high (USD $55.32, $55.65 and $55.46, respectively) due to low PrEP client volume observed in the clinical trial. Increasing client volume (scaled Department of Health scenario) reduced cost per‐person month estimates to USD $15.48, $26.40 and $13.99, respectively.Conclusions: As designed, individualized effective use counselling increased the cost of standard‐of‐care PrEP delivery by 89%, group‐based community health effective use counselling increased the cost of standard‐of‐care PrEP delivery by 11%. These estimates can inform cost‐effectiveness and budget impact analysis for PrEP provision with effective use counselling services.

24 February 2025 in Journal of the International AIDS Society
Verified
Journal Article
Open access
DKDavid Kaftan
David Kaftan
MSMonisha Sharma
Monisha Sharma
DRDanielle Resar
Danielle Resar
MMMasabho Milali
Masabho Milali
EMEdinah Mudimu
Edinah Mudimu
ABAnna Bershteyn
Anna Bershteyn
Introduction: Affordable HIV prevention tools are needed in Eastern and Southern Africa (ESA). Several promising long‐acting pre‐exposure prophylaxis (LA‐PrEP) products are available or in development. However, ESA settings face severe healthcare resource constraints. We aimed to estimate the threshold price at which LA‐PrEP products could be cost‐effective in three ESA settings. Methods: We adapted an agent‐based model, EMOD‐HIV, to simulate LA‐PrEP (monthly oral, 2‐ and 6‐monthly injectable) rollout in South Africa, Zimbabwe and Kenya. Due to uncertainties about LA‐PrEP use, we examined a range of coverages (5%−20% of HIV‐negative sexually active adults) and extents to which LA‐PrEP use will be concentrated among those most at risk (prioritized rollout from higher‐ to lower‐risk groups vs. uniform rollout among sexually active adults). To evaluate a 20‐year commitment to LA‐PrEP delivery, we assumed LA‐PrEP was scaled up to target coverage from 2025 to 2030 and maintained at target levels before ending in 2045. We estimated maximum per‐dose and per‐year LA‐PrEP costs that achieve cost‐effectiveness (<US$500 per disability‐adjusted life‐year averted) over 35 years (until 2060), compared to a scenario of daily oral PrEP only. Sensitivity analyses varied PrEP scale‐up speeds and eligible populations. Results: Risk‐prioritized LA‐PrEP for 5% of adults was projected to avert 11–21% of HIV acquisitions across settings, with 3–5 times more HIV acquisitions averted and 3–5 times higher maximum cost compared to non‐prioritized rollout. Six‐monthly injectable PrEP supported the highest per‐dose cost: in the scenario with the most cost‐effective LA‐PrEP use (5% risk‐prioritized rollout), the maximum per‐dose price in South Africa was $52.99 (95% CI: $48.82–$57.21), in Zimbabwe $14.64 (95% CI: $12.04–$17.38) and in western Kenya $7.50 (95% CI: $6.73–$8.27). For monthly oral PrEP, corresponding per‐dose costs were $5.02 (95% CI: $4.67–$5.37), $1.45 (95% CI: $1.10–$1.79) and $0.87 (95% CI: $0.80–$0.93). Results were sensitive to eligible population and prioritization, and moderately sensitive to scale‐up speed and product effectiveness. Conclusions: LA‐PrEP is likely to require reduced pricing and/or risk‐prioritized rollout to be cost‐effective in ESA.

20 November 2023 in Scientific African
Verified
Journal Article
Open access
ZCZviiteyi Chazuka
Zviiteyi Chazuka
EMEdinah Mudimu
Edinah Mudimu
DMDephney Mathebula
Dephney Mathebula

13 September 2024 in Results in Control and Optimization
Verified
Journal Article
Open access
ZCZviiteyi Chazuka
Zviiteyi Chazuka
CCC.W. Chukwu
C.W. Chukwu
DMD. Mathebula
D. Mathebula
EMEdinah Mudimu
Edinah Mudimu